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Abstract
Background: Pneumococcal disease is the leading cause of vaccine-preventable death in children younger than
5 years of age worldwide. The World Health Organization recommends pneumococcal conjugate vaccine as a
priority for inclusion into national childhood immunization programmes. Pneumococcal vaccine has yet to be
included as part of the national vaccination programme in Malaysia although it has been available in the country
since 2005. This study sought to estimate the disease burden of pneumococcal disease in Malaysia and to assess
the cost effectiveness of routine infant vaccination with PCV7.
Methods: A decision model was adapted taking into consideration prevalence, disease burden, treatment costs
and outcomes for pneumococcal disease severe enough to result in a hospital admission. Disease burden were
estimated from the medical records of 6 hospitals. Where local data was unavailable, model inputs were obtained
from international and regional studies and from focus group discussions. The model incorporated the effects of
herd protection on the unvaccinated adult population.
Results: At current vaccine prices, PCV7 vaccination of 90% of a hypothetical 550,000 birth cohort would incur
costs of RM 439.6 million (US$128 million). Over a 10 year time horizon, vaccination would reduce episodes of
pneumococcal hospitalisation by 9,585 cases to 73,845 hospitalisations with cost savings of RM 37.5 million
(US$10.9 million) to the health system with 11,422.5 life years saved at a cost effectiveness ratio of RM 35,196
(US$10,261) per life year gained.
Conclusions: PCV7 vaccination of infants is expected to be cost-effective for Malaysia with an incremental cost per
life year gained of RM 35,196 (US$10,261). This is well below the WHO’s threshold for cost effectiveness of public
health interventions in Malaysia of RM 71,761 (US$20,922).
Background
Streptococcus pneumoniae (S. pneumoniae) is a bacterial
pathogen responsible for significant morbidity and mortal-
ity worldwide, particularly in young children and the
elderly [1-4]. Non-invasive pneumococcal disease is caused
by S. pneumoniae infection of mucosal tissue, such as the
upper respiratory tract, middle ear and sinuses which can
lead to non-bacteraemic pneumonia, acute otitis media
(OM) and sinusitis. The more severe invasive pneumococ-
cal disease (IPD) occurs when bacteria disseminates into
the bloodstream and central nervous system resulting in
bacteraemia, meningitis, and bacteraemic pneumonia
[5-8]. It is estimated that up to one million children under
5 years of age die every year from pneumococcal pneumo-
nia, meningitis and sepsis [9,10]. Data from the World
Health Organization (WHO) shows that pneumococcal
disease is the leading cause of vaccine-preventable death
in children younger than 5 years of age worldwide [11]. In
2009, pneumonia was the 4
th leading cause of death in
Ministry of Health (MOH) Hospitals in Malaysia with
10.4% of hospital mortality while respiratory diseases were
the 3
rd leading cause of hospitalisation with 9.4% of
discharges [12].
Although antibiotic treatment for pneumococcal dis-
eases are available, there are still unmet medical needs
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vention via vaccination is an important intervention
that could reduce the incidence of pneumococcal
infection and its complications [5]. One of the avail-
able vaccines in Malaysia at the time of this study was
Prevenar
®, a Heptavalent Pneumococcal Conjugate
Vaccine (PCV7), indicated for the active immunization
of infants and children from 6 weeks through 9 years
of age. Prevenar contains saccharides of the capsular
antigen of S. pneumoniae s e r o t y p e s4 ,6 B ,9 V ,1 4 ,1 8 C ,
19F and 23F individually conjugated to the diphtheria
Cross Reactive Material 197 (CRM197) protein [13].
Following recommendation by the Strategic Advisory
Group of Experts (SAGE) on immunization, the World
Health Organization considers that the pneumococcal
conjugate vaccine should be a priority for inclusion
in national childhood immunization programmes [6].
As of January 2010, high pneumococcal vaccination
coverage has been achieved in 43 countries as part of
national immunization programmes or through other
means [14]. PCV7 has been available in Malaysia since
2005 but has yet to be included in the national vacci-
nation programme.
The herd effect, also known as herd immunity, is
defined as the reduction of infection or disease in the
unimmunised segment as a result of immunising a pro-
portion of the population [15-17]. This effect is seen in
vaccination with PCV7, where it has been shown to be
able to reduce nasopharyngeal carriage of vaccine strains
in immunised children, resulting in subsequent interrup-
tion of transmission to unimmunised contacts [18]. In
countries where PCV7 has been included as part of the
routine vaccination schedule, surveillance data has
demonstrated that vaccination of specific populations not
only provides immunised individuals with protection
against pneumococcal disease, but also reduces the risk
of developing pneumococcal illness in unimmunised
individuals.. For example, in the United States, it is esti-
mated that PCV7 has prevented more than twice as
many cases of pneumococcal disease through indirect
effects [19]. Another study from 8 states across the Uni-
ted States reported a 28% reduction in incidence of pneu-
mococcal disease and a 55% reduction in conjugate
vaccine serotypes in adults above 50 years of age after the
introduction of PCV7 infant vaccination in year 2000
[20]. A study of households in Pennsylvania also found
an 80% reduction (OR = 0.2, 95% CI 0.1-0.8) in the odds
ratio of bacteraemic pneumococcal pneumonia among
adults in households where young children had received
PCV7 vaccination [21].
This study sought to estimate the disease burden of
pneumococcal disease in Malaysia and to assess the cost
effectiveness of routine infant vaccination with PCV7.
Methods
A decision analytic model based on PCV7 immunization
in the United Kingdom by McIntosh [22] was adapted to
determine the effects and cost effectiveness of universal
infant PCV7 vaccination compared with no vaccination
for a hypothetical birth cohort of 550,000 infants over a
10-year time horizon. Similar to McIntosh, the model
incorporated hospitalised cases of pneumococcal disease
based on age-specific disease incidence rates. These
included pneumococcal meningitis, pneumococcal septi-
caemia and pneumococcal pneumonia as well as a pro-
portion of unspecified pneumonia and otitis media. All
cases of pneumococcal infections requiring hospitalisa-
tion from pre-admission to post-admission follow-ups in
the outpatient setting were included. Demographic
assumptions within the model are described in Table 1.
The analysis was performed from the payer perspective.
This study was approved by the ethics committees of
the National University of Malaysia (FF-12-2008) and
the Ministry of Health Malaysia (NMRR-08-664-1819).
Disease incidence estimation
The incidence of hospitalised pneumococcal disease was
estimated from review of medical records from 2006-
2007 at six tertiary hospitals. These six hospitals were
selected to broadly represent Malaysia geographically as
shown in Table 2.
Cases of hospitalised pneumococcal disease were pri-
marily identified by International Statistical Classification
of Diseases and Related Health Problems 10th Revision
(ICD-10) classification at discharge. Additional patients
positive for streptococcus pneumonia were also identified
through review of laboratory records to ensure more
c o m p r e h e n s i v ed a t ac a p t u r e .F o rt h ep u r p o s eo ft h i s
study, ICD-10 pneumococcal disease codes included
were: pneumococcal meningitis (code G00.1), pneumo-
coccal septicaemia (code A40.3), and pneumonia due to
S. pneumonia (code J13). In addition, the study identified
other unspecified pneumonia (codes J15.9, J18, J18.9) and
otitis media (codes H65, H66, H67). Thirty percent of
all-cause pneumonia cases and 36% of meningitis and
bacteraemia were attributed to S. pneumoniae [22-24].
All patient data was de-identified prior to analysis.
The incidence of pneumococcal disease by clinical
presentation for children and adults in each hospital
catchment area was calculated from epidemiological
data from the six hospitals. Due to lack of any published
estimates, assumptions about the population catchment
and treatment provision by hospitals were obtained
from a focus group discussion consisting of experienced
clinicians and paramedics conducted in October 2008.
The catchment population of UKM Medical Centre was
assumed to be the entire population of the local district
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The catchment area for the remaining five hospitals was
assumed to be the entire 2007 population of the urban
area and 5% of the state population where the hospitals
were located [25,26]. Each hospital was assumed to
provide treatment for 50% of cases within its catchment
area. The national incidence rate by age group and pre-
s e n t a t i o ni n2 0 0 7w a se s t i m a t ed as the average disease
rate across the six hospitals. The incidence rate was var-
ied in sensitivity analysis.
Table 1 Model assumptions on pneumococcal disease and vaccination effects
Parameter Value Source
Population distribution
Birth cohort 550,000 [25,26]
20-39 years age group 8,770,937 [25,26]
40-64 years group 5,536,238 [25,26]
≥ 65 years group 1,051,371 [25,26]
Life expectancy at birth (years) 74.2 [30]
PCV7 vaccine coverage 495,000 90% of birth cohort [12]
PCV7 vaccine compliance 100%
Pneumococcal disease incidence
S. pneumonia isolated 100%
Unspecified meningitis and bacteraemia 36% [24]
All cause pneumonia 30% [23]
Paediatric fatality rate
Meningitis 0.2 [31]
Bacteraemia 0.1 [31]
All cause pneumonia 0% [31]
Otitis media 0% [31]
Adult fatality rate
Meningitis 9.0% [32]
Bacteraemia 4.6% [32]
All cause pneumonia 0.17% [32]
Otitis media 0% [32]
PCV7 serotype coverage 66.7% [28]
PCV7 efficacy in infants
Pneumococcal meningitis 97.4% [27]
Pneumococcal bacteraemia 97.4% [27]
All cause pneumonia 6% [27]
Otitis media 7% [27]
PCV7 efficacy decline over time (efficacy waning)
≤ 5 years post-vaccination 1% p.a. [22]
6-10 years post-vaccination 3% p.a. [22]
Reduction on IPD in adults (herd effects)
20-39 years group 32% [29]
40-64 years group 8% [29]
≥ 65 years group 18% [29]
Table 2 Primary sources of epidemiological data
Hospital Type of Hospital Region Catchment population
(% national population)
National University of Malaysia Medical Centre Teaching hospital Kuala Lumpur, Central Peninsula 603,692 (2.2%)
Hospital Tuanku Jaafar, Seremban Ministry of Health Seremban, Central Peninsula 311,898 (1.1%)
Hospital Universiti Sains Malaysia Teaching hospital Kota Bharu, Peninsula East Coast 341,232 (1.3%)
Hospital Tengku Ampuan Afzan, Kuantan Ministry of Health Kuantan, Peninsula East Coast 368,805 (1.4%)
Hospital Sultanah Bahiyah, Alor Setar Ministry of Health Alor Setar, Northern Peninsula 221,054 (0.8%)
Sarawak General Hospital Ministry of Health Kuching, East Malaysia 687,413 (2.5%)
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Vaccine efficacy in the target population is assumed to be
97.4% against pneumococcal meningitis and pneumococ-
cal bacteraemia, 6% against all-cause pneumonia and 7%
against otitis media in line with the Northern California
Kaiser Permanente (NCKP) study [27]. Serotype coverage
was adjusted to 66.7% based on the results of a local sur-
vey to account for potential differences in the serotype
landscape in Malaysia relative to the NCKP trial [28].
Vaccination was assumed to be administrated in 4 doses
at 2, 4, 6 and 12 to 15 months of age with efficacy com-
mencing from the 1
st dose. PCV7 vaccination coverage is
assumed at 90% of the birth cohort as the coverage of
most vaccinations under the existing Malaysian national
immunisation programme exceeds 95% [12]. A 100% com-
pliance rate (i.e. that all infants in the cohort would to
complete all 4 doses of vaccination) was assumed in order
to reduce model complexity.
Consistent with previous economic studies on PCV7,
the efficacy of PCV7 in the vaccinated birth cohort is
assumed to decline by 1% per year up to the age of
5 years and by 3% per year from 6 to 10 years of age [22].
The effect of herd protection in the unvaccinated
population is incorporated into the model by assuming
reduction in the incidence of inpatient IPD by 32% in
the 20-39 years group, 8% in the 40-64 years group and
18% in the ≥ 65 years group respectively [29]. The
model assumptions on vaccine effects are described in
Table 1.
Outcomes estimation
Population data and life expectancy were based on 2006
population estimates for the various age cohorts in
Malaysia. The life expectancy for infants was estimated
to be 74.2 years [30] and the birth cohort was estimated
to be 550,000 infants. The national population distribu-
tion by age group was 8,770,937 in the 20-39 years age
group, 5,536,238 in the 40-64 years group and 1,051,371
in the greater than 65 years group [30]. Due to the
absence of local age-specific mortality data, rates for pae-
diatric and adult fatality were adopted from Singapore
and Hong Kong respectively [31,32]. These assumptions
are described in Table 1.
Cost estimation
The cost of pneumococcal disease was determined from
the perspective of the Malaysian healthcare system. These
included the costs of direct medical resources including
costs of physician consultation, all drugs consumed during
admission and follow-up episodes, hospitalisation, diag-
nostic tests and surgical interventions. The treatment of
an episode of pneumococcal disease covered the period
from pre-admission care to hospitalisation and post-dis-
charge out-patient follow-up. The costs of outpatient
treatment that was not linked to any hospital admission
were excluded.
Resources used in outpatient pre-admission and post-
discharge treatment were estimated by the focus group
discussion. The focus group delineated clinical pathways
of treatment for pneumococcal disease which was then
used to identify resources consumed to treat various
clinical presentations.
Unit costs used in this analysis are shown in Table 3.
These were obtained by a top-down costing approach to
estimate cost of treatment in each hospital using the
Clinical Costing Software Version 1.0 (CCM Ver. 1.0)
developed by the Case-Mix Unit of the UKM Medical
Centre. The software estimates unit costs for inpatient
and outpatient treatment by distributing costs into three
levels beginning with overhead cost centres, followed by
intermediate cost centres and finally patient cost centres.
Within each level, costs are distributed according to allo-
cation factors such as floor size, staff counts, patient
counts and inpatient days. The aforementioned focus
group estimated that patient care in the Malaysian
healthcare setting would typically have 2 to 3 visits to
outpatient care prior to hospitalisation for pneumococcal
disease. Therefore, depending on the disease manifesta-
tion, pre-admission and post-discharge outpatient treat-
ment costs vary for an episode of hospitalisation as
shown in Table 3.
The following conventions were used for imputing
capital and recurrent costs:
Capital Cost
Cost of buildings and fixtures have been included. The
life span of buildings was estimated at 20 years with an
annual depreciation of 5%, costs of instruments, trans-
portation/vehicles have been determined at a life span
of 5 years with an annual depreciation of 20%. Only
areas and vehicles used within the activity scope of this
study were considered.
Recurrent Cost
Recurrent costs included cost of labour and supplies.
Labour costs included salaries, bonuses and allowances
to healthcare personnel. Costs of supplies were calculated
as the total cost of all purchases of medication and non-
medication items. Utility costs due to water, electricity
supply, telephone and waste maintenance were calculated
for each activity within the scope of the study.
Both costs and benefits are discounted at 3% in the
primary analysis. In sensitivity analysis costs were dis-
counted at 3% while benefits were not discounted [33].
All costs were measured in 2007 Malaysian Ringgit
(RM). The 2007 average exchange rates of US$1 to
RM3.43 and €1t oR M 4 . 7 1w e r ea p p l i e dt oc u r r e n c y
conversions [34].
Aljunid et al. BMC Infectious Diseases 2011, 11:248
http://www.biomedcentral.com/1471-2334/11/248
Page 4 of 10Costs effectiveness analysis
A cost effectiveness model was used to estimate the
impact of routine PCV7 vaccination of a birth cohort of
550,000 infants compared with no vaccination over a
10-year time horizon [22]. Model inputs included epide-
miological and cost data from the six hospitals, focus
group discussions and published sources as described
above.
Cost-effectiveness was expressed as cost per life-year
gained (LYG) where years of life are retained due to
death avoided by means of an intervention, in this case
universal infant vaccination. LYG was determined by tak-
ing into consideration average life expectancy minus the
age of death due to IPD (LYG = Average life expectancy -
age of expected death). Therefore, LYG was calculated by
Malaysian life expectancy (74.2 years) minus the child or
adult’s age at the time of death due to disease. The incre-
mental cost per life year gained was calculated by com-
paring routine infant vaccination with PCV7 against the
alternative of no routine vaccination.
Sensitivity analysis
Sensitivity analysis was conducted by reducing the cost
from a four dose to three dose regimen. Based on
results from other studies we assume no decline in effi-
cacy from the dose reduction [35,36]. One way sensitiv-
ity analyses were also performed by varying the herd
effects of vaccination [29], vaccine efficacy rates against
paediatric cases of all-cause pneumonia and otitis
media, and the serotype coverage of PCV7 [27,37].
Lastly, sensitivity analysis was performed by varying the
discount rate on outcome to 0% (i.e. undiscounted out-
come) while the maintaining a 3% discount on costs
[33].
Results
Diseases incidence
Based on data from the six hospitals, the estimated age-
specific incidence of hospitalised IPD, all-cause pneumo-
nia and all-cause otitis media in Malaysia is as shown in
Table 4. The highest rates of hospitalisation were
Table 3 Model assumptions on costs
Cost Parameter Value (RM) Remarks
PCV7 vaccination cost (per infant) 888 4 dose regimen at current market price of RM222 per dose
Pre-admission costs (adult and paediatric)
Meningitis, pneumonia and otitis media 206 Focus group discussion
Septicaemia 309
Post-discharge costs (adult and paediatric)
Meningitis, pneumonia and otitis media 309 Focus group discussion
Septicaemia 1,236
Paediatric cost per episode of hospitalised infection
Pneumococcal bacteraemia 7,076
Pneumococcal meningitis 5,399
Hospitalised all-Cause pneumonia 2,592 Weighted average cost of treatment
for each episode of disease
calculated using data from
6 local hospitals
Severe otitis media 2,554
Weighted cost per episode of IPD 3,191
Adult cost per episode of hospitalised infection
Pneumococcal bacteraemia 6,141
Pneumococcal meningitis 3,504 Weighted average cost of treatment
for each episode of disease
calculated using data from
6 local hospitals
Hospitalised all-Cause pneumonia 2,830
Weighted cost per episode of IPD 3,768
Discount rate on costs and outcomes 3%
Building use life 20 years
Building depreciation 5% p.a.
Instrument and vehicle use life 5 years
Instrument and vehicle depreciation 20% p.a.
Note: Costs are measured in year 2007 Malaysian Ringgit (RM).
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years of age at 20.406 hospitalisations per 1000 popula-
tion and in children under 4 years of age at 7.658 per
1000 population.
Costs
A tt h ep r o p o s e dm a r k e tp r i c eo fR M 2 2 2p e rd o s ei na
four dose regimen, a total vaccine cost of RM439.59
million would be incurred to vaccinate 495,000 infants,
equivalent to 90% of the birth cohort of 550,000 as
shown in Table 5. The direct medical cost of an episode
of pneumococcal disease in a paediatric population var-
ies from RM2,554 for an episode of hospitalised otitis
media to RM7,076 for an episode of hospitalised pneu-
mococcal septicaemia. The corresponding cost for adult
care varies from RM2,830 for an episode of hospitalised
all-cause pneumonia to RM6,141 for an episode of hos-
pitalised pneumococcal septicaemia as shown in Table 3.
Outcomes
As shown in Table 5 over the 10-year time horizon of the
model, vaccination of the birth cohort is estimated to
prevent 4,474 cases of paediatric hospitalisations. These
included 2,036 cases of IPD (consisting of 1,538 cases of
bacteraemia and 498 meningitis), 2,289 cases of all-cause
pneumonia and 149 cases of severe otitis media. Vaccina-
tion would also save 336 lives by reducing paediatric
mortality from 639 to 303 deaths with 10,242.7 life years
gained. With the addition of herd effects, a further 5,111
hospitalised cases of IPD and 72 deaths in adults would
be avoided with 1,179.8 years of life saved.
Cost effectiveness
Our model estimates that without vaccination, pneumo-
coccal disease hospitalisations cost the health system
approximately RM256 million (US$74.6 million) over 10
years. Routine infant vaccination will reduce hospitalisa-
tion costs by RM 37.5 million, to RM218.3 million over
the same period.
Comparing routine infant vaccination with no vaccina-
tion over a 10 year time horizon, vaccination gains
11,422.5 life years at an additional cost of RM402 million.
Thus, routine infant PCV7 vaccination incurs an incre-
mental cost (ICER) of RM 35,196, (US$10,261) per life
year gained (LYG) if herd protection in the adult popula-
tion is included as shown in Table 5.
WHO guidelines on generalized cost-effectiveness ana-
lyses for public health interventions considers programmes
to be cost effective when the cost-effectiveness ratio is
between one and three times the country’s GDP per capita
[38]. As Malaysia’s GDP per capita was RM23,920 (US
$6,974) in 2007 [34], an ICER of RM 35,196 for routine
PCV7 vaccination would be considered cost effective as it
is well within Malaysia’s cost effectiveness threshold of
RM71,761 (US$20,922).
Sensitivity Analyses
As shown in Table 6 the model ICER results were sensi-
tive to variations in the number of doses of PCV7, the
incidence rate of meningitis and septicaemia, and the
efficacy of the vaccine against IPD. Varying the dose
Table 4 Age specific incidence of pneumococcal disease by presentation
Clinical
presentation
Annual incidence by age group and clinical presentation
(per 1000 population ª)
0-4 5-19 20-39 40-64 ≥ 65
Pneumococcal meningitis 0.347 0.057 0.035 0.027 0.046
Pneumococcal bacteraemia 0.463 0.1 0.152 0.593 2.533
Pneumococcal pneumonia 2.396 0.391 0.32 1.124 6.34
All-cause pneumonia 7.658 1.261 0.933 3.525 20.406
All-cause otitis media 0.491 0.337 0.152 0.294 0.165
ª Population data by age-group for each hospital catchment area for 2006-2007 was used as the denominator for calculation.
Source: Department of Statistics, Malaysia.
Table 5 Outcomes and cost effectiveness
No
vaccination
PCV7
vaccination
Incremental
Hospitalised cases (n)
Total 83,430 73,845 -9,585
Paediatric 51,933 47,459 -4,474
Adult 31,497 26,386 -5,111
Deaths (n)
Total 1,074 666 -408
Paediatric 639 303 -336
Adult 435 363 -72
Life Years Lost (years)
Total 26,154.00 14,731.60 -11,422.50
Paediatric 19,482.60 9,239.90 -10,242.70
Adult 6,671.40 5,491.60 -1,179.80
Costs (RM million)
Total 255.8 657.9 402
Vaccine 0 439.6 439.6
Hospitalisation episodes 255.8 218.3 -37.5
Paediatric 137.2 118.9 -18.3
Adult 118.7 99.4 -19.3
ICER (per life year gained) RM35,196
(US$10,261)
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LYG. Varying other model parameters such as herd
effects on the adult population, the vaccine serotype
coverage, cohort vaccination rate, vaccine efficacy or dis-
ease incidence did not result in the ICER exceeding
Malaysia’s cost effectiveness threshold of RM71,761.
Discussion
The results from the cost-effectiveness analysis show
that routine infant vaccination with PCV7 can lead to a
reduction in the incidence of all manifestations of pneu-
mococcal disease and potentially save lives. In the pae-
diatric population, universal vaccination is estimated to
prevent 4,474 hospitalisations over a 10-year period.
When the analysis included the impact of herd protec-
tion on the adult population, an additional 5,111 cases
of hospitalised IPD and 72 deaths are estimated to be
prevented.
At an ICER of RM 35,196 per LYG, the result of this
s t u d yc o m p a r e sf a v o u r a b l ya g a i n s tt h eW H O ’sr e c o m -
mended cost effectiveness threshold for Malaysia of
RM71,761 as well as another large publically funded
health programme in Malaysia that is the MOH chronic
haemodialysis programme which has reported CER of
RM33,642 in 2001 (equivalent to RM38,240 in 2007
after adjusting for general inflation) [39,34].
A meta-analysis by Isaacman examined the cost effec-
tiveness of Prevenar vaccination in several countries as
shown in Table 7 [40]. Similar to the current study, the
studies included were based on similar assumptions of 4
doses of vaccine administered, 10-year model timeline,
10-year vaccine protection, and cost and benefits dis-
c o u n t e da t3 %p e ry e a r .T h e ys h o w e dt h a tt h ec o s t -
effectiveness evidence for PCV7 supported the initiation
of national immunization programs in countries consid-
ered. The cost effectiveness ratio of our study (at
RM35,196 or € 7,479 per LYG) appears to be compar-
able to studies evaluated by Isaacman. However, such
direct comparisons should be made cautiously as this
present study has methodological differences to those
considered in Isaacman’s review. Specifically, the current
study did not consider long-term cost savings from
pneumococcal sequelae avoided and other outpatient
cost savings.
The results of this study support the implementation
of a nationwide programme of infant vaccination. We
employed highly conservative incidence rates of pneu-
monia and otitis media in the paediatric population as
only hospitalised (i.e. severe cases) were included in the
model. The cost of pneumococcal disease treated exclu-
sively in the outpatient setting was not included due to
lack of reliable epidemiological and costing data. Our
Table 6 Sensitivity analysis
Model parameters Range of values ICER (RM)
Dose regimen 3-4 doses 25,576 - 35,196
Herd effects
Lower 95% bound on herd effects
Age 20-30 23% 37,648
Age 40-64 1%
Age ≥ 65 11%
Higher herd effects
Age 20-30 41% 31,886
Age 40-64 20%
Age ≥ 65 31%
Discounting of costs (benefits not discounted) 3% 33,140
Vaccine serotype coverage 61.7-71.7% 34,208 - 36,242
% cohort vaccinated 80-100% 31,711 - 32,751
Vaccine efficacy
IPD 82.7% to 99.9% 34,377 - 40,896
Pneumonia -1.5% to 11% 34,802 - 35,788
Otitis Media 4.1% to 9.7% 35,184 - 35,209
Disease incidence
Meningitis 26,703 - 41.777
Bacteraemia 50% to 200%
of base case
21,629 - 50,437
Pneumonia 34,723 - 35,433
Otitis Media 35,166 - 35,212
Aljunid et al. BMC Infectious Diseases 2011, 11:248
http://www.biomedcentral.com/1471-2334/11/248
Page 7 of 10results do not estimate the true burden of disease seen
in the community which are treated in the outpatient
setting and therefore underestimates cost effectiveness.
This can be regarded as a limitation since cost savings
from reduction of pneumococcal disease treated in out-
patient settings are likely to be considerable.
If the burden of disease in outpatients were also
included in the model, the results would likely show
greater cost effectiveness from outpatient pneumonia and
otitis media cases prevented. Other potential effects of
vaccination on related clinical presentations of pneumo-
coccal disease such as sinusitis and septic arthritis were
not included in the analysis. The analysis also did not
consider the effects or cost consequences of long term
sequelae (deafness, brain damage, focal neural deficit and
chronic seizures) on paediatric survivors of pneumococ-
cal meningitis.
We note that there were several other limitations to
this study. Firstly, there was limited local data upon
which to base estimates and thus assumptions based on
international sources and clinician focus group discus-
sion were necessary. This included the assumptions
about hospital catchment and treatment populations.
Secondly, the implementation of ICD coding varies
across Malaysian hospitals affecting our ability to capture
all cases through ICD codes alone. To avoid underesti-
mating the pneumococcal disease incidence in Malaysia
using ICD-10 only, patients were also identified by review
of laboratory records.
Thirdly, the analysis excluded the programmatic costs
that would be incurred in implementing a national vac-
cination programme. Finally, the model also assumes
the indirect benefits in reduced hospitalisations are
accrued from the vaccination of a single cohort only
although it may be debatable if herd effects can be fully
realized from vaccination of a single cohort only.
Reduction of antibiotic resistance is another factor
favouring implementation of pneumococcal vaccination.
Data from the U.S. suggests significant reductions in anti-
biotic prescribing for paediatric cases of otitis media have
occurred following licensing of PCV7 [37]. Similarly, a
reduction in the incidence of antibiotic-non-susceptible
IPD has also been reported, and has been attributed to
widespread PCV7 vaccination [41]. This potential benefit
is of significant importance in Malaysia where S. pneumo-
niae isolates have exhibited increased antibiotic resistance.
Since this study was conducted, newer pneumococcal
vaccines with wider serotype coverage such as PCV13 have
since become available. Nevertheless, the analysis presented
in this study shows clearly that even with the narrow sero-
type coverage from PCV7, routine infant vaccination is
cost effective. Further analysis based on newer pneumococ-
cal vaccines such as PCV13 would demonstrate even better
cost effectiveness as the protection afforded from vaccina-
tion would be even greater than with PCV7.
Conclusions
The results presented here show that universal infant
vaccination with PCV7 has an incremental cost per life
year gained of RM 35,196 (US$10,261) when only direct
costs of hospitalisation and the impact of herd protec-
tion in the unvaccinated adult population are included.
These cost savings from both the direct and indirect
effects of vaccination show that a national infant vacci-
nation programme with PCV7 is a cost-effective inter-
vention for Malaysia. Thus, it can be considered a
worthwhile investment for protection of the population
against pneumococcal disease.
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